ID   ATM_HUMAN               Reviewed;        3056 AA.
AC   Q13315; B2RNX5; O15429; Q12758; Q16551; Q93007; Q9NP02; Q9UCX7;
DT   27-APR-2001, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 2.
DT   02-NOV-2010, entry version 138.
DE   RecName: Full=Serine-protein kinase ATM;
DE            EC=2.7.11.1;
DE   AltName: Full=Ataxia telangiectasia mutated;
DE            Short=A-T mutated;
GN   Name=ATM;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   MEDLINE=96154672; PubMed=8589678; DOI=10.1093/hmg/4.11.2025;
RA   Savitsky K., Sfez S., Tagle D.A., Ziv Y., Sartiel A., Collins F.S.,
RA   Shiloh Y., Rotman G.;
RT   "The complete sequence of the coding region of the ATM gene reveals
RT   similarity to cell cycle regulators in different species.";
RL   Hum. Mol. Genet. 4:2025-2032(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=97343327; PubMed=9199932;
RA   Platzer M., Rotman G., Bauer D., Uziel T., Savitsky K., Bar-Shira A.,
RA   Gilad S., Shiloh Y., Rosenthal A.;
RT   "Ataxia-telangiectasia locus: sequence analysis of 184 kb of human
RT   genomic DNA containing the entire ATM gene.";
RL   Genome Res. 7:592-605(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANTS CYS-49;
RP   ARG-1054; PHE-1420; ILE-2079 AND ALA-2287.
RX   MEDLINE=96275738; PubMed=8665503;
RA   Vorechovsky I., Rasio D., Luo L., Monaco C., Hammarstroem L.,
RA   Webster A.D.B., Zaloudik J., Barbanti-Brodano G., James M.R.,
RA   Russo G., Croce C.M., Negrini M.;
RT   "The ATM gene and susceptibility to breast cancer: analysis of 38
RT   breast tumors reveals no evidence for mutation.";
RL   Cancer Res. 56:2726-2732(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ASN-1983.
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-24.
RX   MEDLINE=97263790; PubMed=9108147; DOI=10.1093/nar/25.9.1678;
RA   Savitsky K., Platzer M., Uziel T., Gilad S., Sartiel A., Rosenthal A.,
RA   Elroy-Stein O., Shiloh Y., Rotman G.;
RT   "Ataxia-telangiectasia: structural diversity of untranslated sequences
RT   suggests complex post-transcriptional regulation of ATM gene
RT   expression.";
RL   Nucleic Acids Res. 25:1678-1684(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1369, AND VARIANT AT
RP   2546-SER--ILE-2548 DEL.
RX   MEDLINE=96381439; PubMed=8789452; DOI=10.1093/hmg/5.1.145;
RA   Byrd P.J., McConville C.M., Cooper P., Parkhill J., Stankovic T.,
RA   McGuire G.M., Thick J.A., Taylor A.M.R.;
RT   "Mutations revealed by sequencing the 5' half of the gene for ataxia
RT   telangiectasia.";
RL   Hum. Mol. Genet. 5:145-149(1996).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-2756.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1332-3056, AND VARIANTS AT
RP   2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL AND SER-2860 DEL.
RC   TISSUE=Fibroblast;
RX   MEDLINE=95312868; PubMed=7792600; DOI=10.1126/science.7792600;
RA   Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L.,
RA   Tagle D.A., Smith S., Uziel T., Sfez S., Ashkenazi M., Pecker I.,
RA   Frydman M., Harnik R., Patanjali S.R., Simmons A., Clines G.A.,
RA   Sartiel A., Gatti R.A., Chessa L., Sanal O., Lavin M.F.,
RA   Jaspers N.G.J., Taylor A.M.R., Arlett C.F., Miki T., Weissman S.M.,
RA   Lovett M., Collins F.S., Shiloh Y.;
RT   "A single ataxia telangiectasia gene with a product similar to PI-3
RT   kinase.";
RL   Science 268:1749-1753(1995).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1332-3056.
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1349-3056.
RX   MEDLINE=96105020; PubMed=8521392;
RA   Rasio D., Negrini M., Croce C.M.;
RT   "Genomic organization of the ATM locus involved in ataxia-
RT   telangiectasia.";
RL   Cancer Res. 55:6053-6057(1995).
RN   [12]
RP   PHOSPHORYLATION.
RX   MEDLINE=97126018; PubMed=8969240; DOI=10.1074/jbc.271.52.33693;
RA   Chen G., Lee E.Y.-H.P.;
RT   "The product of the ATM gene is a 370-kDa nuclear phosphoprotein.";
RL   J. Biol. Chem. 271:33693-33697(1996).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   MEDLINE=97203148; PubMed=9050866; DOI=10.1073/pnas.94.5.1840;
RA   Brown K.D., Ziv Y., Sadanandan S.N., Chessa L., Collins F.S.,
RA   Shiloh Y., Tagle D.A.;
RT   "The ataxia-telangiectasia gene product, a constitutively expressed
RT   nuclear protein that is not up-regulated following genome damage.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:1840-1845(1997).
RN   [14]
RP   SUBCELLULAR LOCATION, AND VARIANTS AT 2546-SER--ILE-2548 DEL AND
RP   TYR-2824.
RX   MEDLINE=97294602; PubMed=9150358; DOI=10.1038/sj.onc.1201037;
RA   Watters D., Khanna K.K., Beamish H., Birrell G., Spring K., Kedar P.,
RA   Gatei M., Stenzel D., Hobson K., Kozlov S., Zhang N., Farrell A.,
RA   Ramsay J., Gatti R.A., Lavin M.F.;
RT   "Cellular localisation of the ataxia-telangiectasia (ATM) gene product
RT   and discrimination between mutated and normal forms.";
RL   Oncogene 14:1911-1921(1997).
RN   [15]
RP   CATALYTIC ACTIVITY.
RX   MEDLINE=97141775; PubMed=8988033;
RA   Jung M., Kondratyev A., Lee S.A., Dimtchev A., Dritschilo A.;
RT   "ATM gene product phosphorylates I kappa B-alpha.";
RL   Cancer Res. 57:24-27(1997).
RN   [16]
RP   INTERACTION WITH ABL1.
RX   MEDLINE=97311400; PubMed=9168117; DOI=10.1038/387520a0;
RA   Shafman T., Khanna K.K., Kedar P., Spring K., Kozlov S., Yen T.,
RA   Hobson K., Gatei M., Zhang N., Watters D., Egerton M., Shiloh Y.,
RA   Kharbanda S., Kufe D., Lavin M.F.;
RT   "Interaction between ATM protein and c-Abl in response to DNA
RT   damage.";
RL   Nature 387:520-523(1997).
RN   [17]
RP   ENZYME REGULATION.
RX   PubMed=9766667;
RA   Sarkaria J.N., Tibbetts R.S., Busby E.C., Kennedy A.P., Hill D.E.,
RA   Abraham R.T.;
RT   "Inhibition of phosphoinositide 3-kinase related kinases by the
RT   radiosensitizing agent wortmannin.";
RL   Cancer Res. 58:4375-4382(1998).
RN   [18]
RP   INTERACTION WITH TP53, AND CATALYTIC ACTIVITY.
RX   MEDLINE=99057351; PubMed=9843217; DOI=10.1038/3882;
RA   Khanna K.K., Keating K.E., Kozlov S., Scott S., Gatei M., Hobson K.,
RA   Taya Y., Gabrielli B., Chan D., Lees-Miller S.P., Lavin M.F.;
RT   "ATM associates with and phosphorylates p53: mapping the region of
RT   interaction.";
RL   Nat. Genet. 20:398-400(1998).
RN   [19]
RP   INTERACTION WITH BETA-ADAPTIN.
RX   MEDLINE=98374320; PubMed=9707615; DOI=10.1073/pnas.95.17.10146;
RA   Lim D.-S., Kirsch D.G., Canman C.E., Ahn J.-H., Ziv Y., Newman L.S.,
RA   Darnell R.B., Shiloh Y., Kastan M.B.;
RT   "ATM binds to beta-adaptin in cytoplasmic vesicles.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10146-10151(1998).
RN   [20]
RP   PHOSPHORYLATION OF TP53.
RX   MEDLINE=98404273; PubMed=9733514; DOI=10.1126/science.281.5383.1674;
RA   Banin S., Moyal L., Shieh S.-Y., Taya Y., Anderson C.W., Chessa L.,
RA   Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y.;
RT   "Enhanced phosphorylation of p53 by ATM in response to DNA damage.";
RL   Science 281:1674-1677(1998).
RN   [21]
RP   PHOSPHORYLATION OF TP53, AND MUTAGENESIS OF ASP-2870 AND ASN-2875.
RX   MEDLINE=98404274; PubMed=9733515; DOI=10.1126/science.281.5383.1677;
RA   Canman C.E., Lim D.-S., Cimprich K.A., Taya Y., Tamai K.,
RA   Sakaguchi K., Appella E., Kastan M.B., Siliciano J.D.;
RT   "Activation of the ATM kinase by ionizing radiation and
RT   phosphorylation of p53.";
RL   Science 281:1677-1679(1998).
RN   [22]
RP   DNA-BINDING.
RX   MEDLINE=99432198; PubMed=10500142; DOI=10.1073/pnas.96.20.11134;
RA   Smith G.C.M., Cary R.B., Lakin N.D., Hann B.C., Teo S.-H., Chen D.J.,
RA   Jackson S.P.;
RT   "Purification and DNA binding properties of the ataxia-telangiectasia
RT   gene product ATM.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:11134-11139(1999).
RN   [23]
RP   PHOSPHORYLATION OF BRCA1.
RX   MEDLINE=20018333; PubMed=10550055; DOI=10.1126/science.286.5442.1162;
RA   Cortez D., Wang Y., Qin J., Elledge S.J.;
RT   "Requirement of ATM-dependent phosphorylation of brca1 in the DNA
RT   damage response to double-strand breaks.";
RL   Science 286:1162-1166(1999).
RN   [24]
RP   IDENTIFICATION OF ATM AS MEMBER OF BASC.
RX   MEDLINE=20245492; PubMed=10783165; DOI=10.1101/gad.827000;
RA   Wang Y., Cortez D., Yazdi P., Neff N., Elledge S.J., Qin J.;
RT   "BASC, a super complex of BRCA1-associated proteins involved in the
RT   recognition and repair of aberrant DNA structures.";
RL   Genes Dev. 14:927-939(2000).
RN   [25]
RP   PHOSPHORYLATION OF NBN.
RX   MEDLINE=20227312; PubMed=10766245; DOI=10.1038/35007091;
RA   Lim D.-S., Kim S.-T., Xu B., Maser R.S., Lin J., Petrini J.H.J.,
RA   Kastan M.B.;
RT   "ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway.";
RL   Nature 404:613-617(2000).
RN   [26]
RP   PHOSPHORYLATION OF NBN.
RX   MEDLINE=20296355; PubMed=10839545; DOI=10.1038/35013089;
RA   Wu X., Ranganathan V., Weisman D.S., Heine W.F., Ciccone D.N.,
RA   O'Neill T.B., Crick K.E., Pierce K.A., Lane W.S., Rathbun G.,
RA   Livingston D.M., Weaver D.T.;
RT   "ATM phosphorylation of Nijmegen breakage syndrome protein is required
RT   in a DNA damage response.";
RL   Nature 405:477-482(2000).
RN   [27]
RP   PHOSPHORYLATION OF CTIP.
RX   MEDLINE=20365735; PubMed=10910365; DOI=10.1038/35018134;
RA   Li S., Ting N.S.Y., Zheng L., Chen P.-L., Ziv Y., Shiloh Y.,
RA   Lee E.Y.-H.P., Lee W.-H.;
RT   "Functional link of BRCA1 and ataxia telangiectasia gene product in
RT   DNA damage response.";
RL   Nature 406:210-215(2000).
RN   [28]
RP   PHOSPHORYLATION OF NBN.
RX   MEDLINE=20264381; PubMed=10802669; DOI=10.1038/75508;
RA   Gatei M., Young D., Cerosaletti K.M., Desai-Mehta A., Spring K.,
RA   Kozlov S., Lavin M.F., Gatti R.A., Concannon P., Khanna K.K.;
RT   "ATM-dependent phosphorylation of nibrin in response to radiation
RT   exposure.";
RL   Nat. Genet. 25:115-119(2000).
RN   [29]
RP   PHOSPHORYLATION OF TERF1.
RX   MEDLINE=21369915; PubMed=11375976; DOI=10.1074/jbc.M011534200;
RA   Kishi S., Zhou X.Z., Ziv Y., Khoo C., Hill D.E., Shiloh Y., Lu K.P.;
RT   "Telomeric protein Pin2/TRF1 as an important ATM target in response to
RT   double strand DNA breaks.";
RL   J. Biol. Chem. 276:29282-29291(2001).
RN   [30]
RP   INTERACTION WITH RAD17.
RX   MEDLINE=21312051; PubMed=11418864; DOI=10.1038/35082110;
RA   Bao S., Tibbetts R.S., Brumbaugh K.M., Fang Y., Richardson D.A.,
RA   Ali A., Chen S.M., Abraham R.T., Wang X.-F.;
RT   "ATR/ATM-mediated phosphorylation of human Rad17 is required for
RT   genotoxic stress responses.";
RL   Nature 411:969-974(2001).
RN   [31]
RP   PHOSPHORYLATION OF FANCD2.
RX   PubMed=12086603; DOI=10.1016/S0092-8674(02)00747-X;
RA   Taniguchi T., Garcia-Higuera I., Xu B., Andreassen P.R., Gregory R.C.,
RA   Kim S.-T., Lane W.S., Kastan M.B., D'Andrea A.D.;
RT   "Convergence of the fanconi anemia and ataxia telangiectasia signaling
RT   pathways.";
RL   Cell 109:459-472(2002).
RN   [32]
RP   PHOSPHORYLATION BY ARK5.
RX   MEDLINE=22393479; PubMed=12409306; DOI=10.1074/jbc.M206025200;
RA   Suzuki A., Kusakai G., Kishimoto A., Lu J., Ogura T., Lavin M.F.,
RA   Esumi H.;
RT   "Identification of a novel protein kinase mediating Akt survival
RT   signaling to the ATM protein.";
RL   J. Biol. Chem. 278:48-53(2003).
RN   [33]
RP   AUTOPHOSPHORYLATION AT SER-1981, SUBUNIT, FUNCTION, AND MUTAGENESIS OF
RP   SER-1981.
RX   PubMed=12556884; DOI=10.1038/nature01368;
RA   Bakkenist C.J., Kastan M.B.;
RT   "DNA damage activates ATM through intermolecular autophosphorylation
RT   and dimer dissociation.";
RL   Nature 421:499-506(2003).
RN   [34]
RP   INTERACTION WITH DCLRE1C.
RX   PubMed=15456891; DOI=10.1128/MCB.24.20.9207-9220.2004;
RA   Zhang X., Succi J., Feng Z., Prithivirajsingh S., Story M.D.,
RA   Legerski R.J.;
RT   "Artemis is a phosphorylation target of ATM and ATR and is involved in
RT   the G2/M DNA damage checkpoint response.";
RL   Mol. Cell. Biol. 24:9207-9220(2004).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=15302935; DOI=10.1073/pnas.0404720101;
RA   Beausoleil S.A., Jedrychowski M., Schwartz D., Elias J.E., Villen J.,
RA   Li J., Cohn M.A., Cantley L.C., Gygi S.P.;
RT   "Large-scale characterization of HeLa cell nuclear phosphoproteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:12130-12135(2004).
RN   [36]
RP   INTERACTION WITH EEF1E1.
RX   PubMed=15680327; DOI=10.1016/j.cell.2004.11.054;
RA   Park B.-J., Kang J.W., Lee S.W., Choi S.-J., Shin Y.K., Ahn Y.H.,
RA   Choi Y.H., Choi D., Lee K.S., Kim S.;
RT   "The haploinsufficient tumor suppressor p18 upregulates p53 via
RT   interactions with ATM/ATR.";
RL   Cell 120:209-221(2005).
RN   [37]
RP   INTERACTION WITH MYST1.
RX   PubMed=15923642; DOI=10.1128/MCB.25.12.5292-5305.2005;
RA   Gupta A., Sharma G.G., Young C.S.H., Agarwal M., Smith E.R.,
RA   Paull T.T., Lucchesi J.C., Khanna K.K., Ludwig T., Pandita T.K.;
RT   "Involvement of human MOF in ATM function.";
RL   Mol. Cell. Biol. 25:5292-5305(2005).
RN   [38]
RP   FUNCTION IN HISTONE MRNA DEGRADATION ACTIVITY.
RX   PubMed=16086026; DOI=10.1038/nsmb972;
RA   Kaygun H., Marzluff W.F.;
RT   "Regulated degradation of replication-dependent histone mRNAs requires
RT   both ATR and Upf1.";
RL   Nat. Struct. Mol. Biol. 12:794-800(2005).
RN   [39]
RP   INTERACTION WITH HTATIP, AUTOPHOSPHORYLATION AT SER-1981, AND
RP   ACETYLATION.
RX   PubMed=16141325; DOI=10.1073/pnas.0504211102;
RA   Sun Y., Jiang X., Chen S., Fernandes N., Price B.D.;
RT   "A role for the Tip60 histone acetyltransferase in the acetylation and
RT   activation of ATM.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:13182-13187(2005).
RN   [40]
RP   AUTOPHOSPHORYLATION AT SER-367; SER-1893 AND SER-1981, FUNCTION, MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF SER-367; SER-1893 AND SER-1981.
RX   PubMed=16858402; DOI=10.1038/sj.emboj.7601231;
RA   Kozlov S.V., Graham M.E., Peng C., Chen P., Robinson P.J., Lavin M.F.;
RT   "Involvement of novel autophosphorylation sites in ATM activation.";
RL   EMBO J. 25:3504-3514(2006).
RN   [41]
RP   INTERACTION WITH ATMIN.
RX   PubMed=17525732; DOI=10.1038/sj.emboj.7601733;
RA   Kanu N., Behrens A.;
RT   "ATMIN defines an NBS1-independent pathway of ATM signalling.";
RL   EMBO J. 26:2933-2941(2007).
RN   [42]
RP   ACETYLATION AT LYS-3016, FUNCTION, AND MUTAGENESIS OF LYS-3016 AND
RP   LYS-3018.
RX   PubMed=17923702; DOI=10.1128/MCB.01382-07;
RA   Sun Y., Xu Y., Roy K., Price B.D.;
RT   "DNA damage-induced acetylation of lysine 3016 of ATM activates ATM
RT   kinase activity.";
RL   Mol. Cell. Biol. 27:8502-8509(2007).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-72; SER-85; THR-86;
RP   SER-367; THR-373; SER-1981 AND THR-1985, AND MASS SPECTROMETRY.
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [44]
RP   INTERACTION WITH CEP164.
RX   PubMed=18283122; DOI=10.1101/gad.1627708;
RA   Sivasubramaniam S., Sun X., Pan Y.R., Wang S., Lee E.Y.;
RT   "Cep164 is a mediator protein required for the maintenance of genomic
RT   stability through modulation of MDC1, RPA, and CHK1.";
RL   Genes Dev. 22:587-600(2008).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1981 AND SER-2996, AND
RP   MASS SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [46]
RP   INTERACTION WITH OBFC2B.
RX   PubMed=18449195; DOI=10.1038/nature06883;
RA   Richard D.J., Bolderson E., Cubeddu L., Wadsworth R.I.M., Savage K.,
RA   Sharma G.G., Nicolette M.L., Tsvetanov S., McIlwraith M.J.,
RA   Pandita R.K., Takeda S., Hay R.T., Gautier J., West S.C., Paull T.T.,
RA   Pandita T.K., White M.F., Khanna K.K.;
RT   "Single-stranded DNA-binding protein hSSB1 is critical for genomic
RT   stability.";
RL   Nature 453:677-681(2008).
RN   [47]
RP   INTERACTION WITH DDX1.
RX   PubMed=18710941; DOI=10.1128/MCB.01053-08;
RA   Li L., Monckton E.A., Godbout R.;
RT   "A role for DEAD box 1 at DNA double-strand breaks.";
RL   Mol. Cell. Biol. 28:6413-6425(2008).
RN   [48]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RA   Colinge J., Superti-Furga G., Bennett K.L.;
RL   Submitted (OCT-2008) to UniProtKB.
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1883; SER-1981 AND
RP   SER-2996, AND MASS SPECTROMETRY.
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [50]
RP   INTERACTION WITH TELO2 AND TTI1.
RX   PubMed=20427287; DOI=10.1074/jbc.M110.121699;
RA   Kaizuka T., Hara T., Oshiro N., Kikkawa U., Yonezawa K., Takehana K.,
RA   Iemura S., Natsume T., Mizushima N.;
RT   "Tti1 and Tel2 are critical factors in mammalian target of rapamycin
RT   complex assembly.";
RL   J. Biol. Chem. 285:20109-20116(2010).
RN   [51]
RP   VARIANTS AT GLY-2424; 2546-SER--ILE-2548 DEL AND CYS-2827.
RX   MEDLINE=96335701; PubMed=8755918;
RA   McConville C.M., Stankovic T., Byrd P.J., McGuire G.M., Yao Q.-Y.,
RA   Lennox G.G., Taylor A.M.R.;
RT   "Mutations associated with variant phenotypes in ataxia-
RT   telangiectasia.";
RL   Am. J. Hum. Genet. 59:320-330(1996).
RN   [52]
RP   VARIANT AT 2546-SER--ILE-2548 DEL, AND VARIANT ILE-2438.
RX   MEDLINE=96404417; PubMed=8808599;
RA   Wright J., Teraoka S., Onengut S., Tolun A., Gatti R.A., Ochs H.D.,
RA   Concannon P.;
RT   "A high frequency of distinct ATM gene mutations in ataxia-
RT   telangiectasia.";
RL   Am. J. Hum. Genet. 59:839-846(1996).
RN   [53]
RP   VARIANTS AT 705-PHE--PRO-707 AND 2546-SER--ILE-2548 DEL, AND VARIANTS
RP   CYS-49; LEU-858; ARG-1054; PHE-1420 AND ARG-1691.
RX   MEDLINE=96390593; PubMed=8797579;
RA   Vorechovsky I., Luo L., Lindblom A., Negrini M., Webster A.D.B.,
RA   Croce C.M., Hammarstroem L.;
RT   "ATM mutations in cancer families.";
RL   Cancer Res. 56:4130-4133(1996).
RN   [54]
RP   VARIANT AT 705-PHE--PRO-707, AND VARIANTS LEU-858 AND ARG-1054.
RX   MEDLINE=97196780; PubMed=9043869;
RA   Vorechovsky I., Luo L., Prudente S., Chessa L., Russo G., Kanariou M.,
RA   James M.R., Negrini M., Webster A.D.B., Hammarstroem L.;
RT   "Exon-scanning mutation analysis of the ATM gene in patients with
RT   ataxia-telangiectasia.";
RL   Eur. J. Hum. Genet. 4:352-355(1996).
RN   [55]
RP   VARIANT AT ARG-2867.
RX   MEDLINE=96305462; PubMed=8698354; DOI=10.1007/s004390050202;
RA   Baumer A., Bernthaler U., Wolz W., Hoehn H., Schindler D.;
RT   "New mutations in the ataxia telangiectasia gene.";
RL   Hum. Genet. 98:246-249(1996).
RN   [56]
RP   VARIANTS AT 2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; SER-2860
RP   DEL AND GLY-2904.
RX   MEDLINE=96254972; PubMed=8845835; DOI=10.1093/hmg/5.4.433;
RA   Gilad S., Khosravi R., Shkedy D., Uziel T., Ziv Y., Savitsky K.,
RA   Rotman G., Smith S., Chessa L., Jorgensen T.J., Harnik R., Frydman M.,
RA   Sanal O., Portnoi S., Goldwicz Z., Jaspers N.G.J., Gatti R.A.,
RA   Lenoir G., Lavin M.F., Tatsumi K., Wegner R.-D., Shiloh Y.,
RA   Bar-Shira A.;
RT   "Predominance of null mutations in ataxia-telangiectasia.";
RL   Hum. Mol. Genet. 5:433-439(1996).
RN   [57]
RP   VARIANTS TPLL THR-1407; HIS-1682; HIS-1910; LYS-2164; SER-2396;
RP   GLY-2424; PRO-2442; 2546-SER--ILE-2548 DEL; ALA-2695; ARG-2722;
RP   VAL-2725; LEU-2732; LYS-2810 DEL; 2871-ARG-HIS-2872 DELINS SER AND
RP   VAL-2890, AND VARIANTS BNHL VAL-1040; SER-1463 AND CYS-2832.
RX   MEDLINE=97434220; PubMed=9288106; DOI=10.1038/ng0997-96;
RA   Vorechovsky I., Luo L., Dyer M.J.S., Catovsky D., Amlot P.L.,
RA   Yaxley J.C., Foroni L., Hammarstroem L., Webster A.D.B.,
RA   Yuille M.A.R.;
RT   "Clustering of missense mutations in the ataxia-telangiectasia gene in
RT   a sporadic T-cell leukaemia.";
RL   Nat. Genet. 17:96-99(1997).
RN   [58]
RP   VARIANTS TPLL GLY-2725; PRO-3006 AND CYS-3008.
RX   MEDLINE=97475207; PubMed=9334731; DOI=10.1038/nm1097-1155;
RA   Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S.,
RA   Bar-Shira A., James M.R., Lichter P., Doehner H.;
RT   "Biallelic mutations in the ATM gene in T-prolymphocytic leukemia.";
RL   Nat. Med. 3:1155-1159(1997).
RN   [59]
RP   VARIANT AT CYS-2832.
RX   MEDLINE=98107941; PubMed=9443866; DOI=10.1086/301673;
RA   Telatar M., Teraoka S., Wang Z., Chun H.H., Liang T.,
RA   Castellvi-Bel S., Udar N., Boerresen-Dale A.-L., Chessa L.,
RA   Bernatowska-Matuszkiewicz E., Porras O., Watanabe M., Junker A.,
RA   Concannon P., Gatti R.A.;
RT   "Ataxia-telangiectasia: identification and detection of founder-effect
RT   mutations in the ATM gene in ethnic populations.";
RL   Am. J. Hum. Genet. 62:86-97(1998).
RN   [60]
RP   VARIANTS AT LEU-292; ASP-768; GLN-1001; ARG-1691; ILE-1743; GLY-2424;
RP   2427-LEU-ARG-2428 DEL; 2546-SER--ILE-2548 DEL; ASP-2554; GLY-2668 AND
RP   CYS-2827.
RX   MEDLINE=98130536; PubMed=9463314; DOI=10.1086/301706;
RA   Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P.,
RA   Weber P., Bedenham T., Bradwell A.R., Easton D.F., Lennox G.G.,
RA   Haites N., Byrd P.J., Taylor A.M.R.;
RT   "ATM mutations and phenotypes in ataxia-telangiectasia families in the
RT   British Isles: expression of mutant ATM and the risk of leukemia,
RT   lymphoma, and breast cancer.";
RL   Am. J. Hum. Genet. 62:334-345(1998).
RN   [61]
RP   VARIANT AT 1812-ALA-PHE-1813 DELINS VAL.
RX   MEDLINE=98163439; PubMed=9497252; DOI=10.1086/301755;
RA   Gilad S., Chessa L., Khosravi R., Russell P., Galanty Y., Piane M.,
RA   Gatti R.A., Jorgensen T.J., Shiloh Y., Bar-Shira A.;
RT   "Genotype-phenotype relationships in ataxia-telangiectasia and
RT   variants.";
RL   Am. J. Hum. Genet. 62:551-561(1998).
RN   [62]
RP   VARIANT AT PRO-2656.
RX   MEDLINE=98111350; PubMed=9450874;
RX   DOI=10.1002/(SICI)1096-8628(19980113)75:2<141::AID-AJMG4>3.3.CO;2-8;
RA   Toyoshima M., Hara T., Zhang H., Yamamoto T., Akaboshi S., Nanba E.,
RA   Ohno K., Hori N., Sato K., Takeshita K.;
RT   "Ataxia-telangiectasia without immunodeficiency: novel point mutations
RT   within and adjacent to the phosphatidylinositol 3-kinase-like
RT   domain.";
RL   Am. J. Med. Genet. 75:141-144(1998).
RN   [63]
RP   VARIANT TPLL GLY-2486.
RX   MEDLINE=98241437; PubMed=9573030;
RA   Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R.,
RA   Sigaux F., Stern M.-H.;
RT   "Inactivation of the ATM gene in T-cell prolymphocytic leukemias.";
RL   Blood 91:3920-3926(1998).
RN   [64]
RP   VARIANTS AT 2855-ARG-ILE-2856 AND CYS-3008, AND VARIANT VAL-1853.
RX   MEDLINE=99091900; PubMed=9872980;
RA   Hacia J.G., Sun B., Hunt N., Edgemon K., Mosbrook D., Robbins C.,
RA   Fodor S.P.A., Tagle D.A., Collins F.S.;
RT   "Strategies for mutational analysis of the large multiexon ATM gene
RT   using high-density oligonucleotide arrays.";
RL   Genome Res. 8:1245-1258(1998).
RN   [65]
RP   VARIANT AT 2625-GLU-PRO-2626.
RX   MEDLINE=98180886; PubMed=9521587; DOI=10.1007/s004390050675;
RA   van Belzen M.J., Hiel J.A.P., Weemaes C.M.R., Gabreeels F.J.M.,
RA   van Engelen B.G.M., Smeets D.F.C.M., van den Heuvel L.P.W.J.;
RT   "A double missense mutation in the ATM gene of a Dutch family with
RT   ataxia telangiectasia.";
RL   Hum. Genet. 102:187-191(1998).
RN   [66]
RP   VARIANT AT LEU-2829, AND VARIANTS GLU-126; ASP-514 AND ASN-1853.
RX   MEDLINE=98375694; PubMed=9711876;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:3<186::AID-HUMU6>3.3.CO;2-3;
RA   Sasaki T., Tian H., Kukita Y., Inazuka M., Tahira T., Imai T.,
RA   Yamauchi M., Saito T., Hori T., Hashimoto-Tamaoki T., Komatsu K.,
RA   Nikaido O., Hayashi K.;
RT   "ATM mutations in patients with ataxia telangiectasia screened by a
RT   hierarchical strategy.";
RL   Hum. Mutat. 12:186-195(1998).
RN   [67]
RP   VARIANTS AT ASP-1091 AND ARG-1566, AND VARIANTS LEU-858 AND ARG-1054.
RX   MEDLINE=99006895; PubMed=9792409;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:5<330::AID-HUMU6>3.0.CO;2-H;
RA   Broeks A., de Klein A., Floore A.N., Muijtjens M., Kleijer W.J.,
RA   Jaspers N.G.J., van 't Veer L.J.;
RT   "ATM germline mutations in classical ataxia-telangiectasia patients in
RT   the Dutch population.";
RL   Hum. Mutat. 12:330-337(1998).
RN   [68]
RP   VARIANTS AT ARG-2491 AND GLY-2909.
RX   MEDLINE=99006896; PubMed=9792410;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:5<338::AID-HUMU7>3.0.CO;2-9;
RA   Fukao T., Song X.-Q., Yoshida T., Tashita H., Kaneko H., Teramoto T.,
RA   Inoue R., Katamura K., Mayumi M., Hiratani M., Taniguchi N., Arai J.,
RA   Wakiguchi H., Bar-Shira A., Shiloh Y., Kondo N.;
RT   "Ataxia-telangiectasia in the Japanese population: identification of
RT   R1917X, W2491R, R2909G, IVS33+2T-->A, and 7883del5, the latter two
RT   being relatively common mutations.";
RL   Hum. Mutat. 12:338-343(1998).
RN   [69]
RP   VARIANTS TPLL GLY-2139; VAL-2890 AND CYS-3008.
RX   MEDLINE=98147367; PubMed=9488043; DOI=10.1038/sj.onc.1201603;
RA   Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L.,
RA   Matutes E., Brito-Babapulle V., Vorechovsky I., Dyer M.J.S.,
RA   Catovsky D.;
RT   "ATM is usually rearranged in T-cell prolymphocytic leukaemia.";
RL   Oncogene 16:789-796(1998).
RN   [70]
RP   ERRATUM.
RA   Yuille M.A.R., Coignet L.J.A., Abraham S.M., Yaqub F., Luo L.,
RA   Matutes E., Brito-Babapulle V., Vorechovsky I., Dyer M.J.S.,
RA   Catovsky D.;
RL   Oncogene 16:2955-2955(1998).
RN   [71]
RP   VARIANTS BCLL VAL-1853; ARG-1953; PRO-2420; HIS-3008 AND ASN-3018,
RP   VARIANTS MCL LYS-2418 INS AND GLY-2423, AND VARIANT ASN-1853.
RX   MEDLINE=99326327; PubMed=10397742;
RA   Schaffner C., Stilgenbauer S., Rappold G.A., Doehner H., Lichter P.;
RT   "Somatic ATM mutations indicate a pathogenic role of ATM in B-cell
RT   chronic lymphocytic leukemia.";
RL   Blood 94:748-753(1999).
RN   [72]
RP   VARIANTS BCLL CYS-332; ARG-1691 AND GLY-2424.
RX   MEDLINE=99107196; PubMed=9892178;
RA   Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M.,
RA   Albitar M., Reed J.C., Croce C.M.;
RT   "ATM mutations in B-cell chronic lymphocytic leukemia.";
RL   Cancer Res. 59:24-27(1999).
RN   [73]
RP   VARIANT AT PRO-1465.
RX   MEDLINE=99250766; PubMed=10234507; DOI=10.1038/sj.ejhg.5200288;
RA   Izatt L., Vessey C., Hodgson S.V., Solomon E.;
RT   "Rapid and efficient ATM mutation detection by fluorescent chemical
RT   cleavage of mismatch: identification of four novel mutations.";
RL   Eur. J. Hum. Genet. 7:310-320(1999).
RN   [74]
RP   VARIANTS CYS-49; LEU-182; PRO-707; LEU-858; PHE-1420; ALA-1570;
RP   ASN-1853 AND SER-2765.
RX   MEDLINE=20005806; PubMed=10534763;
RX   DOI=10.1002/(SICI)1098-2264(199912)26:4<286::AID-GCC2>3.3.CO;2-O;
RA   Izatt L., Greenman J., Hodgson S.V., Ellis D., Watts S., Scott G.,
RA   Jacobs C., Liebmann R., Zvelebil M.J., Mathew C., Solomon E.;
RT   "Identification of germline missense mutations and rare allelic
RT   variants in the ATM gene in early-onset breast cancer.";
RL   Genes Chromosomes Cancer 26:286-294(1999).
RN   [75]
RP   VARIANTS AT SER-570; CYS-785; GLY-1913; GLY-2016; ASP-2067; CYS-2227;
RP   ASP-2470; VAL-2662 DEL; PRO-2849 AND ARG-2867, AND VARIANTS CYS-49;
RP   LEU-858; ARG-1054; ASN-1853 AND VAL-1853.
RX   MEDLINE=99105918; PubMed=9887333; DOI=10.1093/hmg/8.1.69;
RA   Sandoval N., Platzer M., Rosenthal A., Doerk T., Bendix R.,
RA   Skawran B., Stuhrmann M., Wegner R.-D., Sperling K., Banin S.,
RA   Shiloh Y., Baumer A., Bernthaler U., Sennefelder H., Brohm M.,
RA   Weber B.H.F., Schindler D.;
RT   "Characterization of ATM gene mutations in 66 ataxia telangiectasia
RT   families.";
RL   Hum. Mol. Genet. 8:69-79(1999).
RN   [76]
RP   VARIANTS AT, AND VARIANTS ASN-1454 AND ASN-1853.
RX   MEDLINE=99355715; PubMed=10425038;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:2<156::AID-HUMU7>3.0.CO;2-E;
RA   Castellvi-Bel S., Sheikhavandi S., Telatar M., Tai L.-Q., Hwang M.J.,
RA   Wang Z., Yang Z., Cheng R., Gatti R.A.;
RT   "New mutations, polymorphisms, and rare variants in the ATM gene
RT   detected by a novel SSCP strategy.";
RL   Hum. Mutat. 14:156-162(1999).
RN   [77]
RP   VARIANTS BCLL THR-350; THR-352; ARG-1054; THR-2274 AND ALA-2695.
RX   MEDLINE=99146552; PubMed=10023947; DOI=10.1016/S0140-6736(98)10117-4;
RA   Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J.,
RA   Moss P.A.H., Taylor A.M.R.;
RT   "Inactivation of ataxia telangiectasia mutated gene in B-cell chronic
RT   lymphocytic leukaemia.";
RL   Lancet 353:26-29(1999).
RN   [78]
RP   VARIANT ARG-1054.
RX   MEDLINE=99231468; PubMed=10217116; DOI=10.1016/S0140-6736(05)75199-0;
RA   Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.;
RT   "Missense mutations at ATM gene and cancer risk.";
RL   Lancet 353:1276-1276(1999).
RN   [79]
RP   ERRATUM.
RA   Vorechovsky I., Luo L., Ortmann E., Steinmann D., Doerk T.;
RL   Lancet 354:780-780(1999).
RN   [80]
RP   VARIANTS AT GLU-224; VAL-323; PRO-1420; CYS-2218; 2546-SER--ILE-2548
RP   DEL; GLN-2625; CYS-2832; 2855-ARG-ILE-2856 AND CYS-3008, AND VARIANTS
RP   VAL-1853 AND ILE-2438.
RX   MEDLINE=20275351; PubMed=10817650;
RX   DOI=10.1002/(SICI)1096-8628(20000529)92:3<170::AID-AJMG3>3.0.CO;2-#;
RA   Li A., Swift M.;
RT   "Mutations at the ataxia-telangiectasia locus and clinical phenotypes
RT   of A-T patients.";
RL   Am. J. Med. Genet. 92:170-177(2000).
RN   [81]
RP   VARIANTS AT.
RX   MEDLINE=20334897; PubMed=10873394; DOI=10.1006/mgme.2000.2998;
RA   Becker-Catania S.G., Chen G., Hwang M.J., Wang Z., Sun X., Sanal O.,
RA   Bernatowska-Matuszkiewicz E., Chessa L., Lee E.Y.-H.P., Gatti R.A.;
RT   "Ataxia-telangiectasia: phenotype/genotype studies of ATM protein
RT   expression, mutations, and radiosensitivity.";
RL   Mol. Genet. Metab. 70:122-133(2000).
RN   [82]
RP   VARIANTS MCL LYS-2418 INS; GLY-2423 AND CYS-3008.
RX   MEDLINE=20183964; PubMed=10706620; DOI=10.1073/pnas.050400997;
RA   Schaffner C., Idler I., Stilgenbauer S., Doehner H., Lichter P.;
RT   "Mantle cell lymphoma is characterized by inactivation of the ATM
RT   gene.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:2773-2778(2000).
RN   [83]
RP   VARIANTS [LARGE SCALE ANALYSIS] GLN-23; CYS-49; GLU-126; HIS-140;
RP   GLN-250; PHE-333; CYS-337; HIS-337; ALA-410; SER-504; ASP-514;
RP   TYR-540; VAL-546; LEU-582; PRO-707; GLN-848; LEU-858; SER-872;
RP   TRP-924; ALA-935; ARG-1054; PHE-1179; ILE-1321; TYR-1380; SER-1382;
RP   PHE-1420; MET-1469; CYS-1475; SER-1650; THR-1739; ASN-1853; VAL-1853;
RP   ILE-1916; THR-1945; CYS-1961; ASN-1983; ASP-1991; PHE-2307; PRO-2332;
RP   PHE-2356; LEU-2408; PRO-2442; GLN-2443; ARG-2464; ARG-2492; ALA-2666;
RP   HIS-2719; ARG-2842 AND ASN-2870.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase which activates
CC       checkpoint signaling upon double strand breaks (DSBs), apoptosis
CC       and genotoxic stresses such as ionizing ultraviolet A light (UVA),
CC       thereby acting as a DNA damage sensor. Recognizes the substrate
CC       consensus sequence [ST]-Q. Phosphorylates 'Ser-139' of histone
CC       variant H2AX/H2AFX at double strand breaks (DSBs), thereby
CC       regulating DNA damage response mechanism. Also plays a role in
CC       pre-B cell allelic exclusion, a process leading to expression of a
CC       single immunoglobulin heavy chain allele to enforce clonality and
CC       monospecific recognition by the B-cell antigen receptor (BCR)
CC       expressed on individual B lymphocytes. After the introduction of
CC       DNA breaks by the RAG complex on one immunoglobulin allele, acts
CC       by mediating a repositioning of the second allele to
CC       pericentromeric heterochromatin, preventing accessibility to the
CC       RAG complex and recombination of the second allele. Also involved
CC       in signal transduction and cell cycle control. May function as a
CC       tumor suppressor. Necessary for activation of ABL1 and SAPK.
CC       Phosphorylates p53/TP53, FANCD2, NFKBIA, BRCA1, CTIP, nibrin
CC       (NBN), TERF1, RAD9 and DCLRE1C. May play a role in vesicle and/or
CC       protein transport. Could play a role in T-cell development, gonad
CC       and neurological function. Plays a role in replication-dependent
CC       histone mRNA degradation. Binds DNA ends.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Inhibited by wortmannin.
CC   -!- SUBUNIT: Dimers or tetramers in inactive state. On DNA damage,
CC       autophosphorylation dissociates ATM into monomers rendering them
CC       catalytically active. Binds p53/TP53, ABL1, BRCA1, NBN/nibrin and
CC       TERF1. Part of the BRCA1-associated genome surveillance complex
CC       (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and
CC       the RAD50-MRE11-NBN protein complex. This association could be a
CC       dynamic process changing throughout the cell cycle and within
CC       subnuclear domains. Interacts with RAD17; DNA damage promotes the
CC       association. Interacts with EEF1E1; the interaction, induced on
CC       DNA damage, upregulates TP53. Interacts with DCLRE1C, MYST1, KAT5,
CC       OBFC2B, ATMIN and CEP164. Interacts with AP2B1 and AP3B2; the
CC       interaction occurs in cytoplasmic vesicles (By similarity).
CC       Interacts with TELO2 and TTI1. Interacts with DDX1.
CC   -!- INTERACTION:
CC       Self; NbExp=1; IntAct=EBI-495465, EBI-495465;
CC       Q9NY61:AATF; NbExp=2; IntAct=EBI-495465, EBI-372428;
CC       P00519:ABL1; NbExp=1; IntAct=EBI-495465, EBI-375543;
CC       Q14676:MDC1; NbExp=1; IntAct=EBI-495465, EBI-495644;
CC       Q9BQ15:OBFC2B; NbExp=3; IntAct=EBI-495465, EBI-2120336;
CC       P62136:PPP1CA; NbExp=1; IntAct=EBI-495465, EBI-357253;
CC       P36873:PPP1CC; NbExp=1; IntAct=EBI-495465, EBI-356283;
CC       Q14683:SMC1A; NbExp=1; IntAct=EBI-495465, EBI-80690;
CC       Q9Y4R8:TELO2; NbExp=1; IntAct=EBI-495465, EBI-1043674;
CC       P54274:TERF1; NbExp=6; IntAct=EBI-495465, EBI-710997;
CC       P02340:Tp53 (xeno); NbExp=1; IntAct=EBI-495465, EBI-474016;
CC   -!- SUBCELLULAR LOCATION: Nucleus. Cytoplasmic vesicle. Note=Primarily
CC       nuclear. Found also in endocytic vesicles in association with
CC       beta-adaptin.
CC   -!- TISSUE SPECIFICITY: Found in pancreas, kidney, skeletal muscle,
CC       liver, lung, placenta, brain, heart, spleen, thymus, testis,
CC       ovary, small intestine, colon and leukocytes.
CC   -!- INDUCTION: By ionizing radiation.
CC   -!- DOMAIN: The FATC domain is required for interaction with KAT5.
CC   -!- PTM: Phosphorylated by NUAK1/ARK5. Autophosphorylation on Ser-367,
CC       Ser-1983, Ser-1981 correlates with DNA damage-mediated activation
CC       of the kinase.
CC   -!- PTM: Acetylation, on DNA damage, is required for activation of the
CC       kinase activity, dimer-monomer transition, and subsequent
CC       autophosphorylation on Ser-1981. Acetylated in vitro by
CC       KAT5/TIP60.
CC   -!- DISEASE: Defects in ATM are the cause of ataxia telangiectasia
CC       (AT) [MIM:208900]; also known as Louis-Bar syndrome, which
CC       includes four complementation groups: A, C, D and E. This rare
CC       recessive disorder is characterized by progressive cerebellar
CC       ataxia, dilation of the blood vessels in the conjunctiva and
CC       eyeballs, immunodeficiency, growth retardation and sexual
CC       immaturity. AT patients have a strong predisposition to cancer;
CC       about 30% of patients develop tumors, particularly lymphomas and
CC       leukemias. Cells from affected individuals are highly sensitive to
CC       damage by ionizing radiation and resistant to inhibition of DNA
CC       synthesis following irradiation.
CC   -!- DISEASE: Note=Defects in ATM contribute to T-cell acute
CC       lymphoblastic leukemia (TALL) and T-prolymphocytic leukemia
CC       (TPLL). TPLL is characterized by a high white blood cell count,
CC       with a predominance of prolymphocytes, marked splenomegaly,
CC       lymphadenopathy, skin lesions and serous effusion. The clinical
CC       course is highly aggressive, with poor response to chemotherapy
CC       and short survival time. TPLL occurs both in adults as a sporadic
CC       disease and in younger AT patients.
CC   -!- DISEASE: Note=Defects in ATM contribute to B-cell non-Hodgkin
CC       lymphomas (BNHL), including mantle cell lymphoma (MCL).
CC   -!- DISEASE: Note=Defects in ATM contribute to B-cell chronic
CC       lymphocytic leukemia (BCLL). BCLL is the commonest form of
CC       leukemia in the elderly. It is characterized by the accumulation
CC       of mature CD5+ B lymphocytes, lymphadenopathy, immunodeficiency
CC       and bone marrow failure.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. ATM subfamily.
CC   -!- SIMILARITY: Contains 1 FAT domain.
CC   -!- SIMILARITY: Contains 1 FATC domain.
CC   -!- SIMILARITY: Contains 1 PI3K/PI4K domain.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA86520.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAA86520.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact;
CC       Sequence=AAI37170.1; Type=Erroneous initiation; Note=Translation N-terminally extended;
CC       Sequence=AAI37170.1; Type=Miscellaneous discrepancy; Note=Probable cloning artifact;
CC       Sequence=EAW67111.1; Type=Erroneous gene model prediction;
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/ATM123.html";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/ATM";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/atm/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Ataxia telangiectasia mutated
CC       entry;
CC       URL="http://en.wikipedia.org/wiki/Ataxia_telangiectasia_mutated";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U33841; AAC50289.1; -; mRNA.
DR   EMBL; U82828; AAB65827.1; -; Genomic_DNA.
DR   EMBL; U55757; AAB38309.1; -; Genomic_DNA.
DR   EMBL; U55704; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55705; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55707; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55708; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55709; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55710; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55711; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55712; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55713; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55714; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55715; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55716; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55717; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55718; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55719; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55720; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55721; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55722; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55723; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55724; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55725; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55726; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55727; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55728; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55729; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55730; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55731; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55732; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55733; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55734; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55735; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55736; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55737; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55738; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55739; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55740; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55741; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55742; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55743; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55744; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55745; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55746; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55747; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55748; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55749; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55750; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55751; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55752; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55753; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55754; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55755; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55756; AAB38309.1; JOINED; Genomic_DNA.
DR   EMBL; U55757; AAB38310.1; -; Genomic_DNA.
DR   EMBL; U55726; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55727; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55728; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55729; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55730; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55731; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55732; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55733; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55734; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55735; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55736; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55737; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55738; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55739; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55740; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55741; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55742; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55743; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55744; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55745; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55746; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55747; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55748; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55749; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55750; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55751; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55752; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55753; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55754; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55755; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; U55756; AAB38310.1; JOINED; Genomic_DNA.
DR   EMBL; AP001925; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP005718; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471065; EAW67111.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; U67092; AAC51298.1; -; Genomic_DNA.
DR   EMBL; X91196; CAA62603.1; -; mRNA.
DR   EMBL; AY220758; AAO26044.1; -; Genomic_DNA.
DR   EMBL; U26455; AAA86520.1; ALT_SEQ; mRNA.
DR   EMBL; BC137169; AAI37170.1; ALT_SEQ; mRNA.
DR   IPI; IPI00289986; -.
DR   IPI; IPI00298306; -.
DR   PIR; A43100; A43100.
DR   RefSeq; NP_000042.3; -.
DR   UniGene; Hs.367437; -.
DR   ProteinModelPortal; Q13315; -.
DR   DIP; DIP-182N; -.
DR   IntAct; Q13315; 40.
DR   MINT; MINT-194471; -.
DR   STRING; Q13315; -.
DR   PhosphoSite; Q13315; -.
DR   PRIDE; Q13315; -.
DR   Ensembl; ENST00000278616; ENSP00000278616; ENSG00000149311.
DR   GeneID; 472; -.
DR   KEGG; hsa:472; -.
DR   CTD; 472; -.
DR   GeneCards; GC11P108127; -.
DR   H-InvDB; HIX0010089; -.
DR   HGNC; HGNC:795; ATM.
DR   HPA; CAB000102; -.
DR   MIM; 208900; phenotype.
DR   MIM; 607585; gene.
DR   Orphanet; 100; Ataxia-telangiectasia.
DR   Orphanet; 52416; Mantle cell lymphoma.
DR   PharmGKB; PA61; -.
DR   eggNOG; prNOG08080; -.
DR   HOVERGEN; HBG004304; -.
DR   InParanoid; Q13315; -.
DR   BRENDA; 2.7.11.1; 247.
DR   Pathway_Interaction_DB; bard1pathway; BARD1 signaling events.
DR   Pathway_Interaction_DB; nfkappabcanonicalpathway; Canonical NF-kappaB pathway.
DR   Pathway_Interaction_DB; p38_mkk3_6pathway; p38 MAPK signaling pathway.
DR   Pathway_Interaction_DB; telomerasepathway; Regulation of Telomerase.
DR   Reactome; REACT_1538; Cell Cycle Checkpoints.
DR   Reactome; REACT_216; DNA Repair.
DR   NextBio; 1949; -.
DR   ArrayExpress; Q13315; -.
DR   Bgee; Q13315; -.
DR   CleanEx; HS_ATM; -.
DR   Genevestigator; Q13315; -.
DR   GermOnline; ENSG00000149311; Homo sapiens.
DR   GO; GO:0016023; C:cytoplasmic membrane-bounded vesicle; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; EXP:Reactome.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0004677; F:DNA-dependent protein kinase activity; IDA:BHF-UCL.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0032403; F:protein complex binding; IDA:BHF-UCL.
DR   GO; GO:0046983; F:protein dimerization activity; IDA:BHF-UCL.
DR   GO; GO:0047485; F:protein N-terminus binding; IDA:UniProtKB.
DR   GO; GO:0007050; P:cell cycle arrest; IMP:BHF-UCL.
DR   GO; GO:0071480; P:cellular response to gamma radiation; IDA:BHF-UCL.
DR   GO; GO:0006975; P:DNA damage induced protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0006281; P:DNA repair; IEA:UniProtKB-KW.
DR   GO; GO:0031572; P:G2/M transition DNA damage checkpoint; IMP:BHF-UCL.
DR   GO; GO:0071044; P:histone mRNA catabolic process; IDA:UniProtKB.
DR   GO; GO:0007094; P:mitotic cell cycle spindle assembly checkpoint; IMP:UniProtKB.
DR   GO; GO:0043517; P:positive regulation of DNA damage response,...; IMP:BHF-UCL.
DR   GO; GO:0002331; P:pre-B cell allelic exclusion; ISS:UniProtKB.
DR   GO; GO:0046777; P:protein amino acid autophosphorylation; IDA:BHF-UCL.
DR   GO; GO:0007131; P:reciprocal meiotic recombination; TAS:ProtInc.
DR   GO; GO:0010149; P:senescence; IEP:BHF-UCL.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR015519; Ataxia_Telang_Mut.
DR   InterPro; IPR003152; FATC.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000403; PI3/4_kinase_cat.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR003151; PIK-rel_kinase_FAT.
DR   InterPro; IPR014009; PIK_FAT.
DR   InterPro; IPR021668; TAN.
DR   Gene3D; G3DSA:1.10.1070.11; PI3/4_kinase_cat; 3.
DR   PANTHER; PTHR11139:SF3; Ataxia_Telang_Mut; 1.
DR   Pfam; PF02259; FAT; 1.
DR   Pfam; PF02260; FATC; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF11640; TAN; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF48371; ARM-type_fold; 1.
DR   SUPFAM; SSF56112; Kinase_like; 1.
DR   PROSITE; PS51189; FAT; 1.
DR   PROSITE; PS51190; FATC; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
PE   1: Evidence at protein level;
KW   Acetylation; ATP-binding; Cell cycle; Complete proteome;
KW   Cytoplasmic vesicle; Disease mutation; DNA damage; DNA repair;
KW   DNA-binding; Kinase; Neurodegeneration; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Polymorphism; Serine/threonine-protein kinase;
KW   Transferase; Tumor suppressor.
FT   CHAIN         1   3056       Serine-protein kinase ATM.
FT                                /FTId=PRO_0000088840.
FT   DOMAIN     1960   2566       FAT.
FT   DOMAIN     2712   2962       PI3K/PI4K.
FT   DOMAIN     3024   3056       FATC.
FT   REGION     1373   1382       Interaction with ABL1.
FT   MOD_RES      72     72       Phosphothreonine.
FT   MOD_RES      85     85       Phosphoserine.
FT   MOD_RES      86     86       Phosphothreonine.
FT   MOD_RES     367    367       Phosphoserine; by autocatalysis.
FT   MOD_RES     373    373       Phosphothreonine.
FT   MOD_RES    1883   1883       Phosphoserine.
FT   MOD_RES    1893   1893       Phosphoserine; by autocatalysis.
FT   MOD_RES    1981   1981       Phosphoserine; by autocatalysis.
FT   MOD_RES    1985   1985       Phosphothreonine.
FT   MOD_RES    2996   2996       Phosphoserine.
FT   MOD_RES    3016   3016       N6-acetyllysine.
FT   VARIANT      23     23       R -> Q (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041545.
FT   VARIANT      45     45       R -> W (in dbSNP:rs3218684).
FT                                /FTId=VAR_056678.
FT   VARIANT      49     49       S -> C (in dbSNP:rs1800054).
FT                                /FTId=VAR_010798.
FT   VARIANT     126    126       D -> E (in dbSNP:rs2234997).
FT                                /FTId=VAR_010799.
FT   VARIANT     140    140       D -> H.
FT                                /FTId=VAR_041546.
FT   VARIANT     182    182       V -> L (in dbSNP:rs3218707).
FT                                /FTId=VAR_010800.
FT   VARIANT     224    224       K -> E (in AT).
FT                                /FTId=VAR_010801.
FT   VARIANT     250    250       R -> Q.
FT                                /FTId=VAR_041547.
FT   VARIANT     292    292       P -> L (in AT; associated with lymphoma).
FT                                /FTId=VAR_010802.
FT   VARIANT     323    323       I -> V (in AT).
FT                                /FTId=VAR_010803.
FT   VARIANT     332    332       Y -> C (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010804.
FT   VARIANT     333    333       S -> F.
FT                                /FTId=VAR_041548.
FT   VARIANT     337    337       R -> C (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041549.
FT   VARIANT     337    337       R -> H (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041550.
FT   VARIANT     350    350       A -> T (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010805.
FT   VARIANT     352    352       I -> T (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010806.
FT   VARIANT     410    410       V -> A.
FT                                /FTId=VAR_041551.
FT   VARIANT     504    504       N -> S.
FT                                /FTId=VAR_041552.
FT   VARIANT     514    514       G -> D (in dbSNP:rs2235000).
FT                                /FTId=VAR_010807.
FT   VARIANT     540    540       C -> Y (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041553.
FT   VARIANT     546    546       L -> V (in dbSNP:rs2227924).
FT                                /FTId=VAR_041554.
FT   VARIANT     570    570       F -> S (in AT).
FT                                /FTId=VAR_010808.
FT   VARIANT     582    582       F -> L (in dbSNP:rs2235006).
FT                                /FTId=VAR_041555.
FT   VARIANT     705    707       YSS -> FIP (in AT; might be associated
FT                                with susceptibility to cancer).
FT                                /FTId=VAR_010809.
FT   VARIANT     707    707       S -> P (in dbSNP:rs4986761).
FT                                /FTId=VAR_010810.
FT   VARIANT     761    761       T -> S (in dbSNP:rs2235011).
FT                                /FTId=VAR_056679.
FT   VARIANT     768    768       N -> D (in AT).
FT                                /FTId=VAR_010812.
FT   VARIANT     785    785       R -> C (in AT).
FT                                /FTId=VAR_010813.
FT   VARIANT     788    788       S -> R (in dbSNP:rs641252).
FT                                /FTId=VAR_056680.
FT   VARIANT     814    814       D -> E (in dbSNP:rs3218695).
FT                                /FTId=VAR_056681.
FT   VARIANT     848    848       E -> Q (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041556.
FT   VARIANT     858    858       F -> L (rare polymorphism;
FT                                dbSNP:rs1800056).
FT                                /FTId=VAR_010814.
FT   VARIANT     872    872       P -> S.
FT                                /FTId=VAR_041557.
FT   VARIANT     924    924       R -> W.
FT                                /FTId=VAR_041558.
FT   VARIANT     935    935       T -> A.
FT                                /FTId=VAR_041559.
FT   VARIANT     935    935       T -> M (in dbSNP:rs3218708).
FT                                /FTId=VAR_056682.
FT   VARIANT     942    942       L -> F (in dbSNP:rs3218688).
FT                                /FTId=VAR_056683.
FT   VARIANT     950    950       L -> R (in AT).
FT                                /FTId=VAR_010815.
FT   VARIANT    1001   1001       L -> Q (in AT; associated with T-cell
FT                                acute lymphoblastic leukemia).
FT                                /FTId=VAR_010816.
FT   VARIANT    1040   1040       M -> V (in B-cell non-Hodgkin lymphoma;
FT                                dbSNP:rs3092857).
FT                                /FTId=VAR_010817.
FT   VARIANT    1054   1054       P -> R (in dbSNP:rs1800057).
FT                                /FTId=VAR_010818.
FT   VARIANT    1082   1082       H -> L (in AT).
FT                                /FTId=VAR_010819.
FT   VARIANT    1091   1091       E -> D (in AT).
FT                                /FTId=VAR_010820.
FT   VARIANT    1179   1179       S -> F (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041560.
FT   VARIANT    1313   1313       E -> Q (in dbSNP:rs3092841).
FT                                /FTId=VAR_056684.
FT   VARIANT    1321   1321       M -> I.
FT                                /FTId=VAR_041561.
FT   VARIANT    1380   1380       H -> Y.
FT                                /FTId=VAR_041562.
FT   VARIANT    1382   1382       P -> S.
FT                                /FTId=VAR_041563.
FT   VARIANT    1407   1407       I -> T (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010821.
FT   VARIANT    1420   1420       L -> F (rare polymorphism;
FT                                dbSNP:rs1800058).
FT                                /FTId=VAR_010822.
FT   VARIANT    1420   1420       L -> P (in AT).
FT                                /FTId=VAR_010823.
FT   VARIANT    1427   1427       A -> T (in dbSNP:rs2229021).
FT                                /FTId=VAR_056685.
FT   VARIANT    1454   1454       K -> N.
FT                                /FTId=VAR_010824.
FT   VARIANT    1463   1463       F -> S (in B-cell non-Hodgkin lymphoma).
FT                                /FTId=VAR_010825.
FT   VARIANT    1465   1465       L -> P (in AT).
FT                                /FTId=VAR_010826.
FT   VARIANT    1469   1469       I -> M (in a renal papillary cancer
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041564.
FT   VARIANT    1475   1475       Y -> C.
FT                                /FTId=VAR_041565.
FT   VARIANT    1541   1541       L -> F (in dbSNP:rs3092849).
FT                                /FTId=VAR_056686.
FT   VARIANT    1566   1566       P -> R (in AT).
FT                                /FTId=VAR_010827.
FT   VARIANT    1570   1570       V -> A.
FT                                /FTId=VAR_010828.
FT   VARIANT    1650   1650       N -> S.
FT                                /FTId=VAR_041566.
FT   VARIANT    1682   1682       D -> H (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010829.
FT   VARIANT    1691   1691       S -> R (in AT and B-cell chronic
FT                                lymphocytic leukemia; could be a rare
FT                                polymorphism; dbSNP:rs1800059).
FT                                /FTId=VAR_010830.
FT   VARIANT    1729   1729       V -> L (in dbSNP:rs3092907).
FT                                /FTId=VAR_056687.
FT   VARIANT    1739   1739       N -> T (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041567.
FT   VARIANT    1743   1743       T -> I (in AT; associated with
FT                                preleukemic T-cell proliferation).
FT                                /FTId=VAR_010831.
FT   VARIANT    1812   1813       AF -> V (in AT).
FT                                /FTId=VAR_010832.
FT   VARIANT    1853   1853       D -> N (common polymorphism;
FT                                dbSNP:rs1801516).
FT                                /FTId=VAR_010833.
FT   VARIANT    1853   1853       D -> V (might contribute to B-cell
FT                                chronic lymphocytic leukemia;
FT                                dbSNP:rs1801673).
FT                                /FTId=VAR_010834.
FT   VARIANT    1910   1910       L -> H (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010835.
FT   VARIANT    1913   1913       V -> G (in AT).
FT                                /FTId=VAR_010836.
FT   VARIANT    1916   1916       M -> I (in a breast pleomorphic lobular
FT                                carcinoma sample; somatic mutation).
FT                                /FTId=VAR_041568.
FT   VARIANT    1945   1945       A -> T (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041569.
FT   VARIANT    1953   1953       T -> R (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010837.
FT   VARIANT    1961   1961       Y -> C.
FT                                /FTId=VAR_041570.
FT   VARIANT    1983   1983       S -> N.
FT                                /FTId=VAR_041571.
FT   VARIANT    1991   1991       E -> D (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041572.
FT   VARIANT    2016   2016       D -> G (in AT).
FT                                /FTId=VAR_010838.
FT   VARIANT    2034   2034       R -> Q (in dbSNP:rs3218670).
FT                                /FTId=VAR_056688.
FT   VARIANT    2063   2063       G -> E (in AT).
FT                                /FTId=VAR_010839.
FT   VARIANT    2067   2067       A -> D (in AT).
FT                                /FTId=VAR_010840.
FT   VARIANT    2079   2079       V -> I (in dbSNP:rs1800060).
FT                                /FTId=VAR_010841.
FT   VARIANT    2139   2139       E -> G (in T-prolymphocytic leukemia;
FT                                somatic mutation).
FT                                /FTId=VAR_010842.
FT   VARIANT    2164   2164       E -> K (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010843.
FT   VARIANT    2218   2218       S -> C (in AT).
FT                                /FTId=VAR_010844.
FT   VARIANT    2224   2227       MALR -> IS (in AT).
FT                                /FTId=VAR_010845.
FT   VARIANT    2227   2227       R -> C (in AT).
FT                                /FTId=VAR_010846.
FT   VARIANT    2246   2252       CIKDILT -> H (in AT).
FT                                /FTId=VAR_010847.
FT   VARIANT    2274   2274       A -> T (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010848.
FT   VARIANT    2287   2287       G -> A (in dbSNP:rs1800061).
FT                                /FTId=VAR_010849.
FT   VARIANT    2307   2307       L -> F.
FT                                /FTId=VAR_041573.
FT   VARIANT    2332   2332       L -> P.
FT                                /FTId=VAR_041574.
FT   VARIANT    2335   2335       T -> K (in dbSNP:rs3092831).
FT                                /FTId=VAR_056689.
FT   VARIANT    2356   2356       I -> F (in a renal clear cell carcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041575.
FT   VARIANT    2396   2396       T -> S (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010850.
FT   VARIANT    2408   2408       S -> L (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041576.
FT   VARIANT    2418   2418       K -> KK (in mantle cell lymphoma).
FT                                /FTId=VAR_010851.
FT   VARIANT    2420   2420       A -> P (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010852.
FT   VARIANT    2423   2423       E -> G (in mantle cell lymphoma).
FT                                /FTId=VAR_010853.
FT   VARIANT    2424   2424       V -> G (in AT, B-cell chronic lymphocytic
FT                                leukemia and T-prolymphocytic leukemia;
FT                                associated with increased risk for breast
FT                                cancer).
FT                                /FTId=VAR_010854.
FT   VARIANT    2427   2428       Missing (in AT; associated with T-
FT                                prolymphocytic leukemia).
FT                                /FTId=VAR_010855.
FT   VARIANT    2438   2438       T -> I.
FT                                /FTId=VAR_010856.
FT   VARIANT    2442   2442       Q -> P (in T-prolymphocytic leukemia;
FT                                also in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_010857.
FT   VARIANT    2443   2443       R -> Q (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                /FTId=VAR_041577.
FT   VARIANT    2464   2464       C -> R.
FT                                /FTId=VAR_041578.
FT   VARIANT    2470   2470       Y -> D (in AT).
FT                                /FTId=VAR_010858.
FT   VARIANT    2486   2486       R -> G (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010859.
FT   VARIANT    2491   2491       W -> R (in AT).
FT                                /FTId=VAR_010860.
FT   VARIANT    2492   2492       L -> R.
FT                                /FTId=VAR_041579.
FT   VARIANT    2546   2548       Missing (in AT, T-prolymphocytic leukemia
FT                                and T-cell acute lymphoblastic leukemia).
FT                                /FTId=VAR_010861.
FT   VARIANT    2554   2554       H -> D (in AT).
FT                                /FTId=VAR_010862.
FT   VARIANT    2570   2570       E -> G (in dbSNP:rs28904920).
FT                                /FTId=VAR_056690.
FT   VARIANT    2625   2626       DA -> EP (in AT).
FT                                /FTId=VAR_010864.
FT   VARIANT    2625   2625       D -> Q (in AT; requires 2 nucleotide
FT                                substitutions).
FT                                /FTId=VAR_010863.
FT   VARIANT    2640   2640       T -> I (in dbSNP:rs4988125).
FT                                /FTId=VAR_056691.
FT   VARIANT    2656   2656       L -> P (in AT; partial functional loss).
FT                                /FTId=VAR_010865.
FT   VARIANT    2662   2662       Missing (in AT).
FT                                /FTId=VAR_010866.
FT   VARIANT    2663   2663       Missing (in AT).
FT                                /FTId=VAR_010867.
FT   VARIANT    2666   2666       T -> A (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041580.
FT   VARIANT    2668   2668       E -> G (in AT).
FT                                /FTId=VAR_010868.
FT   VARIANT    2695   2695       G -> A (in T-prolymphocytic leukemia and
FT                                B-cell chronic lymphocytic leukemia).
FT                                /FTId=VAR_010869.
FT   VARIANT    2702   2702       I -> R (in AT).
FT                                /FTId=VAR_010870.
FT   VARIANT    2709   2709       G -> S (in dbSNP:rs3218680).
FT                                /FTId=VAR_056692.
FT   VARIANT    2719   2719       R -> H.
FT                                /FTId=VAR_041581.
FT   VARIANT    2722   2722       L -> R (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010871.
FT   VARIANT    2725   2725       D -> G (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010872.
FT   VARIANT    2725   2725       D -> V (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010873.
FT   VARIANT    2726   2726       A -> V (in AT).
FT                                /FTId=VAR_010874.
FT   VARIANT    2732   2732       F -> L (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010875.
FT   VARIANT    2765   2765       G -> S (may contribute to breast cancer).
FT                                /FTId=VAR_010876.
FT   VARIANT    2810   2810       Missing (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010877.
FT   VARIANT    2824   2824       C -> Y (in AT).
FT                                /FTId=VAR_010878.
FT   VARIANT    2827   2827       F -> C (in AT; mild).
FT                                /FTId=VAR_010879.
FT   VARIANT    2829   2829       P -> L (in AT).
FT                                /FTId=VAR_010880.
FT   VARIANT    2832   2832       R -> C (in AT and B-cell non-Hodgkin
FT                                lymphoma).
FT                                /FTId=VAR_010881.
FT   VARIANT    2842   2842       P -> R (in a lung adenocarcinoma sample;
FT                                somatic mutation).
FT                                /FTId=VAR_041582.
FT   VARIANT    2849   2849       R -> P (in AT).
FT                                /FTId=VAR_010882.
FT   VARIANT    2855   2856       SV -> RI (in AT).
FT                                /FTId=VAR_010884.
FT   VARIANT    2855   2855       S -> R (in AT).
FT                                /FTId=VAR_010883.
FT   VARIANT    2860   2860       Missing (in AT).
FT                                /FTId=VAR_010885.
FT   VARIANT    2867   2867       G -> R (in AT).
FT                                /FTId=VAR_010886.
FT   VARIANT    2870   2870       D -> N.
FT                                /FTId=VAR_041583.
FT   VARIANT    2871   2872       RH -> S (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010887.
FT   VARIANT    2890   2890       L -> V (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010888.
FT   VARIANT    2904   2904       E -> G (in AT).
FT                                /FTId=VAR_010889.
FT   VARIANT    2909   2909       R -> G (in AT).
FT                                /FTId=VAR_010890.
FT   VARIANT    3006   3006       A -> P (in T-prolymphocytic leukemia).
FT                                /FTId=VAR_010892.
FT   VARIANT    3008   3008       R -> C (in AT, T-prolymphocytic leukemia
FT                                and mantle cell lymphoma).
FT                                /FTId=VAR_010893.
FT   VARIANT    3008   3008       R -> H (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010894.
FT   VARIANT    3018   3018       K -> N (in B-cell chronic lymphocytic
FT                                leukemia).
FT                                /FTId=VAR_010895.
FT   MUTAGEN     367    367       S->A: Loss of IR-induced S-367
FT                                autophosphorylation. Reduced correction
FT                                of cell cycle checkpoint defects and DNA-
FT                                repair activity. No effect on S-1893 nor
FT                                S-1981 autophosphorylation.
FT   MUTAGEN    1893   1893       S->A: Loss of IR-induced S-1893
FT                                autophosphorylation. Reduced correction
FT                                of cell cycle checkpoint defects and DNA-
FT                                repair activity. No effect on S-367 nor
FT                                S-1981 autophosphorylation.
FT   MUTAGEN    1981   1981       S->A: Loss of IR-induced S-1981
FT                                autophosphorylation. Reduced correction
FT                                of cell cycle checkpoint defects and DNA-
FT                                repair activity. No effect on S-367 nor
FT                                S-1893 autophosphorylation. No dimer
FT                                disruption.
FT   MUTAGEN    1981   1981       S->D,E: Disrupts the dimer.
FT   MUTAGEN    2870   2870       D->A: Loss of kinase activity.
FT   MUTAGEN    2875   2875       N->K: Loss of kinase activity.
FT   MUTAGEN    3016   3016       K->R: Loss of DNA damage-inducible
FT                                acetylation. Retains constitutive kinase
FT                                activity, but blocks DNA damage-induced
FT                                kinase activation. Disrupts dimer and
FT                                abolishes S-1981 autophosphorylation.
FT   MUTAGEN    3018   3018       K->R: Retains DNA damage-inducible
FT                                acetylation and S-1981
FT                                autophosphorylation.
FT   CONFLICT     46     46       H -> N (in Ref. 7; CAA62603).
FT   CONFLICT     56     56       N -> I (in Ref. 7; CAA62603).
FT   CONFLICT    313    313       Y -> N (in Ref. 7; CAA62603).
FT   CONFLICT    488    488       W -> G (in Ref. 7; CAA62603).
FT   CONFLICT    554    554       T -> A (in Ref. 1; AAC50289).
FT   CONFLICT    750    750       K -> N (in Ref. 1; AAC50289).
FT   CONFLICT    754    754       Q -> K (in Ref. 7; CAA62603).
FT   CONFLICT    887    887       E -> G (in Ref. 7; CAA62603).
FT   CONFLICT   1003   1003       Q -> L (in Ref. 7; CAA62603).
FT   CONFLICT   1049   1049       L -> W (in Ref. 7; CAA62603).
FT   CONFLICT   1089   1089       A -> V (in Ref. 7; CAA62603).
FT   CONFLICT   3003   3003       N -> D (in Ref. 1; AAC50289, 3; AAB38309/
FT                                AAB38310 and 9; AAA86520).
SQ   SEQUENCE   3056 AA;  350687 MW;  C0B4866E1E3199E2 CRC64;
     MSLVLNDLLI CCRQLEHDRA TERKKEVEKF KRLIRDPETI KHLDRHSDSK QGKYLNWDAV
     FRFLQKYIQK ETECLRIAKP NVSASTQASR QKKMQEISSL VKYFIKCANR RAPRLKCQEL
     LNYIMDTVKD SSNGAIYGAD CSNILLKDIL SVRKYWCEIS QQQWLELFSV YFRLYLKPSQ
     DVHRVLVARI IHAVTKGCCS QTDGLNSKFL DFFSKAIQCA RQEKSSSGLN HILAALTIFL
     KTLAVNFRIR VCELGDEILP TLLYIWTQHR LNDSLKEVII ELFQLQIYIH HPKGAKTQEK
     GAYESTKWRS ILYNLYDLLV NEISHIGSRG KYSSGFRNIA VKENLIELMA DICHQVFNED
     TRSLEISQSY TTTQRESSDY SVPCKRKKIE LGWEVIKDHL QKSQNDFDLV PWLQIATQLI
     SKYPASLPNC ELSPLLMILS QLLPQQRHGE RTPYVLRCLT EVALCQDKRS NLESSQKSDL
     LKLWNKIWCI TFRGISSEQI QAENFGLLGA IIQGSLVEVD REFWKLFTGS ACRPSCPAVC
     CLTLALTTSI VPGTVKMGIE QNMCEVNRSF SLKESIMKWL LFYQLEGDLE NSTEVPPILH
     SNFPHLVLEK ILVSLTMKNC KAAMNFFQSV PECEHHQKDK EELSFSEVEE LFLQTTFDKM
     DFLTIVRECG IEKHQSSIGF SVHQNLKESL DRCLLGLSEQ LLNNYSSEIT NSETLVRCSR
     LLVGVLGCYC YMGVIAEEEA YKSELFQKAK SLMQCAGESI TLFKNKTNEE FRIGSLRNMM
     QLCTRCLSNC TKKSPNKIAS GFFLRLLTSK LMNDIADICK SLASFIKKPF DRGEVESMED
     DTNGNLMEVE DQSSMNLFND YPDSSVSDAN EPGESQSTIG AINPLAEEYL SKQDLLFLDM
     LKFLCLCVTT AQTNTVSFRA ADIRRKLLML IDSSTLEPTK SLHLHMYLML LKELPGEEYP
     LPMEDVLELL KPLSNVCSLY RRDQDVCKTI LNHVLHVVKN LGQSNMDSEN TRDAQGQFLT
     VIGAFWHLTK ERKYIFSVRM ALVNCLKTLL EADPYSKWAI LNVMGKDFPV NEVFTQFLAD
     NHHQVRMLAA ESINRLFQDT KGDSSRLLKA LPLKLQQTAF ENAYLKAQEG MREMSHSAEN
     PETLDEIYNR KSVLLTLIAV VLSCSPICEK QALFALCKSV KENGLEPHLV KKVLEKVSET
     FGYRRLEDFM ASHLDYLVLE WLNLQDTEYN LSSFPFILLN YTNIEDFYRS CYKVLIPHLV
     IRSHFDEVKS IANQIQEDWK SLLTDCFPKI LVNILPYFAY EGTRDSGMAQ QRETATKVYD
     MLKSENLLGK QIDHLFISNL PEIVVELLMT LHEPANSSAS QSTDLCDFSG DLDPAPNPPH
     FPSHVIKATF AYISNCHKTK LKSILEILSK SPDSYQKILL AICEQAAETN NVYKKHRILK
     IYHLFVSLLL KDIKSGLGGA WAFVLRDVIY TLIHYINQRP SCIMDVSLRS FSLCCDLLSQ
     VCQTAVTYCK DALENHLHVI VGTLIPLVYE QVEVQKQVLD LLKYLVIDNK DNENLYITIK
     LLDPFPDHVV FKDLRITQQK IKYSRGPFSL LEEINHFLSV SVYDALPLTR LEGLKDLRRQ
     LELHKDQMVD IMRASQDNPQ DGIMVKLVVN LLQLSKMAIN HTGEKEVLEA VGSCLGEVGP
     IDFSTIAIQH SKDASYTKAL KLFEDKELQW TFIMLTYLNN TLVEDCVKVR SAAVTCLKNI
     LATKTGHSFW EIYKMTTDPM LAYLQPFRTS RKKFLEVPRF DKENPFEGLD DINLWIPLSE
     NHDIWIKTLT CAFLDSGGTK CEILQLLKPM CEVKTDFCQT VLPYLIHDIL LQDTNESWRN
     LLSTHVQGFF TSCLRHFSQT SRSTTPANLD SESEHFFRCC LDKKSQRTML AVVDYMRRQK
     RPSSGTIFND AFWLDLNYLE VAKVAQSCAA HFTALLYAEI YADKKSMDDQ EKRSLAFEEG
     SQSTTISSLS EKSKEETGIS LQDLLLEIYR SIGEPDSLYG CGGGKMLQPI TRLRTYEHEA
     MWGKALVTYD LETAIPSSTR QAGIIQALQN LGLCHILSVY LKGLDYENKD WCPELEELHY
     QAAWRNMQWD HCTSVSKEVE GTSYHESLYN ALQSLRDREF STFYESLKYA RVKEVEEMCK
     RSLESVYSLY PTLSRLQAIG ELESIGELFS RSVTHRQLSE VYIKWQKHSQ LLKDSDFSFQ
     EPIMALRTVI LEILMEKEMD NSQRECIKDI LTKHLVELSI LARTFKNTQL PERAIFQIKQ
     YNSVSCGVSE WQLEEAQVFW AKKEQSLALS ILKQMIKKLD ASCAANNPSL KLTYTECLRV
     CGNWLAETCL ENPAVIMQTY LEKAVEVAGN YDGESSDELR NGKMKAFLSL ARFSDTQYQR
     IENYMKSSEF ENKQALLKRA KEEVGLLREH KIQTNRYTVK VQRELELDEL ALRALKEDRK
     RFLCKAVENY INCLLSGEEH DMWVFRLCSL WLENSGVSEV NGMMKRDGMK IPTYKFLPLM
     YQLAARMGTK MMGGLGFHEV LNNLISRISM DHPHHTLFII LALANANRDE FLTKPEVARR
     SRITKNVPKQ SSQLDEDRTE AANRIICTIR SRRPQMVRSV EALCDAYIIL ANLDATQWKT
     QRKGINIPAD QPITKLKNLE DVVVPTMEIK VDHTGEYGNL VTIQSFKAEF RLAGGVNLPK
     IIDCVGSDGK ERRQLVKGRD DLRQDAVMQQ VFQMCNTLLQ RNTETRKRKL TICTYKVVPL
     SQRSGVLEWC TGTVPIGEFL VNNEDGAHKR YRPNDFSAFQ CQKKMMEVQK KSFEEKYEVF
     MDVCQNFQPV FRYFCMEKFL DPAIWFEKRL AYTRSVATSS IVGYILGLGD RHVQNILINE
     QSAELVHIDL GVAFEQGKIL PTPETVPFRL TRDIVDGMGI TGVEGVFRRC CEKTMEVMRN
     SQETLLTIVE VLLYDPLFDW TMNPLKALYL QQRPEDETEL HPTLNADDQE CKRNLSDIDQ
     SFNKVAERVL MRLQEKLKGV EEGTVLSVGG QVNLLIQQAI DPKNLSRLFP GWKAWV
//
